Target: ₹1350
CMP: ₹976.45
UTI Asset Management Company has corrected by about 22 per cent from its peak post 3QFY22 results. The correction was driven by a sharp contraction in top-line MF yields and management guidance of further moderation in FY23.
However, we maintain our positive stance on the stock as core fundamental positives are still in place: a) AUM growth story to continue with improvement in equity and debt market share (AUM CAGR of 22 per cent over FY21-24) and b) improvement in operating profitability driven by cost moderation and increase in top-line revenues aided by non-MF businesses.
UTI Asset Management trades at a valuation of 15.5x FY24E P/E which is at a discount of 40 per cent/28 per cent to HDFCAMC/ NAM’s valuations. We expect the future price performance to be driven by: strong AUM growth driven by superior equity fund performance and renewed focus on distribution; and improvement in operating profitability driven by cost moderation.
We re-iterate UTI AMC as our top-pick in the AMC space with a TP of ₹1,350 valuing it at 22.0x FY24E P/E. A reverse-DCF analysis indicates a conservative AUM and earnings CAGR estimates of 14 per cent and 11 per cent respectively over the next 10 years; indicating upside risks to our target price.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.